Abraxis BioScience is a global biopharmaceutical company dedicated to meeting the needs of critically ill patients, with over 2000 employees worldwide. Abraxis' portfolio includes the world's first protein-based nanoparticle chemotherapeutic compound called nab Technology. From this the company has developed Abraxane, a treatment for metastatic breast cancer. On June 30, 2010, it was announced that Abraxis BioScience would be acquired by Celgene Corporation.